Kihealth Labs · Precision Neurology
Neuro Intercept™
Advancing early molecular detection for neurodegenerative disease.
Neuro Intercept leverages the Intercept IQ™ platform to investigate blood-based molecular biomarkers associated with neurodegeneration, neuroinflammation, and neuronal injury. Our initial research programs are focused on Alzheimer's disease and Multiple Sclerosis, with the long-term vision of expanding into additional neurological disorders.
The Clinical Challenge
Neurodegeneration begins years before diagnosis.
Many neurological diseases begin years — even decades — before clinical diagnosis. By the time cognitive impairment or neurological symptoms become apparent, substantial neuronal injury has often already occurred.
Normal Brain
Healthy neuronal and glial biology.
Silent Molecular Changes
Subclinical shifts in protein handling, energy metabolism, and cellular stress.
Protein Misfolding
Aggregation of amyloid-β, tau, α-synuclein, TDP-43, and related species.
Neuroinflammation
Microglial and astrocytic activation amplify injury.
Neuronal Injury
Synaptic loss, axonal damage, and progressive cell death.
Functional Decline
Subtle cognitive or neurological changes emerge.
Clinical Symptoms
Diagnosis follows only after substantial injury.
Earlier biological insight may create opportunities for earlier intervention, improved monitoring, and more informed therapeutic development.
Blood-Based Molecular Diagnostics
From the brain to the bloodstream.
Advances in molecular technologies are enabling increasingly sensitive detection of circulating biomarkers associated with neurological disease processes.
Brain
Blood–Brain Barrier
Peripheral Molecular Signals
Blood Collection
Advanced Molecular Analysis
Cell-free DNA
Cell-free RNA
Neurodegeneration-associated proteins
Neuroinflammatory proteins
Extracellular vesicles
Epigenetic biomarkers
Immune signaling molecules
Interactive Neurobiology
The biology of neurodegeneration.
Step through the biology to see how molecular events unfold across years — long before clinical symptoms bring patients to medical attention.
Protein Aggregation
Misfolded amyloid-β, tau, α-synuclein, TDP-43, or related species begin to accumulate depending on disease.
Biological Signals
- Amyloid-β / tau aggregation
- α-synuclein deposition
- Prion-like propagation
Neuro Intercept AD
Alzheimer's disease program.
Neuro Intercept AD is being developed to investigate molecular biomarkers associated with Alzheimer's disease biology.
Biological Focus
Potential Applications
Neuro Intercept MS
Multiple Sclerosis program.
Neuro Intercept MS is being developed to investigate molecular biomarkers associated with inflammatory and neurodegenerative processes in Multiple Sclerosis.
- 01
Normal Myelin
Intact myelin sheaths enable saltatory conduction.
- 02
Immune Activation
Autoreactive lymphocytes cross the blood–brain barrier.
- 03
Demyelination
Focal loss of myelin disrupts conduction.
- 04
Axonal Injury
Persistent inflammation drives axonal damage.
- 05
Disease Progression
Cumulative injury manifests as relapses and progression.
Potential Applications
The Platform
The Neuro Intercept™ workflow.
Neuro Intercept integrates multiple orthogonal biomarker classes rather than relying on a single analyte.
Blood Sample
Peripheral venipuncture — no lumbar puncture required.
Plasma Isolation
Controlled fractionation preserves labile analytes.
Cell-Free DNA
High-yield capture of circulating cfDNA fragments.
Proteomics
Neurodegeneration- and inflammation-associated proteins.
Epigenetic Analysis
Tissue-specific methylation signatures.
Inflammatory Biomarkers
Cytokines and immune signaling molecules.
AI Integration
Multi-omic classifiers built on Intercept IQ™.
Molecular Risk Profile
Integrated risk profile across biomarker classes.
Clinical Interpretation
Interpretive research output for downstream use.
Multi-Omic Molecular Intelligence
Neurological disease is a network problem.
Neurological diseases arise from complex biological networks that benefit from integrated multi-omic analysis rather than isolated measurements.
Central Model
Neurodegenerative Biology
Genomics
Epigenomics
Proteomics
Inflammatory Biology
Clinical Data
Longitudinal Monitoring
Artificial Intelligence
Systems Biology
Orthogonal signals, one model
Genomic, epigenomic, proteomic, and inflammatory data capture complementary aspects of neurodegeneration.
Longitudinal by design
Serial molecular measurements convert isolated data points into a dynamic view of disease biology.
Systems- and AI-native
Machine learning identifies multidimensional biomarker signatures no single analyte can reveal.
Artificial Intelligence
Transforming complex molecular data into actionable biological insights.
The Intercept IQ™ platform applies machine learning to convert high-dimensional multi-omic signals into interpretable research outputs.
- Identify multidimensional biomarker signatures
- Detect subtle biological patterns
- Integrate longitudinal patient data
- Support molecular risk classification
- Continuously refine predictive algorithms as clinical data accrue
Analytical Pipeline
- 01Raw Molecular Data
- 02Quality Control
- 03Machine Learning
- 04Pattern Recognition
- 05Risk Assessment
- 06Clinical Research Output
Intended Research Applications
Where Neuro Intercept™ can contribute.
Neuro Intercept is being developed to support molecular research across neurodegenerative and neuroinflammatory disease areas — from early biology to therapeutic response monitoring.
Alzheimer's Disease
- Early biological assessment
- Longitudinal monitoring
- Clinical trials
- Therapeutic response
- Pharmaceutical partnerships
Multiple Sclerosis
- Disease activity monitoring
- Therapy response
- Biomarker discovery
- Longitudinal follow-up
- Clinical research
Future Expansion
Future areas of exploration
- Parkinson's disease
- Amyotrophic lateral sclerosis (ALS)
- Frontotemporal dementia
- Lewy body dementia
- Huntington's disease
- Traumatic brain injury
Scientific Development Strategy
A rigorous, phased path from discovery to translation.
Neuro Intercept™ is being developed through a disciplined pipeline aligned to clinical and regulatory standards for neurology diagnostics.
Discovery
Cohort design and biomarker candidate discovery.
Biomarker Identification
Prioritization of proprietary molecular signatures.
Analytical Validation
Precision, accuracy, LoD, and reproducibility studies.
Clinical Validation
Case-control and prospective studies in intended-use populations.
Research Collaborations
Academic, clinical, and pharmaceutical partnerships.
Regulatory Strategy
IDE / LDT / IVD pathway aligned to intended use.
Commercial Translation
Kihealth CLIA laboratory deployment and clinical availability.
Current Focus
Identification and validation of novel molecular biomarker signatures associated with neurodegenerative disease, and their integration into the Intercept IQ™ multi-omic classifier.
Powered by Intercept IQ™
One platform, multiple neurological programs.
Neuro Intercept™ is one application of the broader Intercept IQ™ platform — a shared multi-omic architecture that supports Beta Intercept™, Onco Intercept™, and future programs.
Intercept IQ™
Underlying multi-omic molecular intelligence platform.
Multi-Omic Analysis
Integrated genomic, epigenomic, and proteomic signals.
AI Integration
Machine learning classifiers on high-dimensional data.
Disease Biology
Modeled against neurodegenerative disease processes.
Neuro Intercept™
Neurology-focused application of the platform.
Research Applications
Biomarker discovery, monitoring, and trial support.
Future Clinical Translation
Path toward validated clinical use.
The Future of Neurodegenerative Diagnostics
Earlier molecular insight. Better clinical decisions.
Neuro Intercept represents Kihealth's neurodegenerative disease research initiative built on the Intercept IQ™ platform. By combining liquid biopsy technologies, multi-omic biomarker discovery, advanced computational biology, and artificial intelligence, Neuro Intercept aims to advance the development of next-generation blood-based diagnostics for Alzheimer's disease, Multiple Sclerosis, and future neurological applications.
Future Neuro Intercept™ Pipeline
A platform designed to expand.
Alzheimer's disease and Multiple Sclerosis are the first two research programs on the Neuro Intercept™ platform. Future programs are envisioned across additional neurological disorders.
Research Program
Neuro Intercept AD
Research Program
Neuro Intercept MS
Future Exploration
Neuro Intercept PD
Future Exploration
Neuro Intercept ALS
Future Exploration
Neuro Intercept FTD
Roadmap
Additional Applications
Future exploration programs are illustrative of the platform's expansion roadmap and are not currently clinically validated or commercially available.